Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity

• Status: Recruiting
• Trial end date: 2026-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Low-intensity focused ultrasound (LIFUS) has been shown to be an effective and safe non-invasive brain stimulation technique, capable of reaching greater brain depth and a greater spatial resolution than other brain stimulation tools. Its use as a potential clinical tool for treatment of neurological disorders is reliant on an understanding of its mechanisms of action. Although it has been shown to induce immediate (online) and prolonged (offline) changes in plasticity in the motor cortex, researchers have not studied its effects on neurotransmitter receptors and ion channels responsible for neuronal signaling in humans. The purpose of this study is to explore the effects of online and offline LIFUS stimulation in tandem with administration of various brain-active drugs, to elucidate the effects of this technique on specific cortical receptors and channels. 20 healthy, screened subjects will be recruited to participate in 5 sessions in-lab. Each session will represent the double-blinded administration of four known and studied pharmacological agents known to safely induce changes in the motor cortex, as well as a placebo. Investigators will use carbamazepine (sodium channel blocker), lorazepam (GABAA positive allosteric modulator), nimodipine (calcium channel blocker), and dextromethorphan (glutamate N-Methyl-D-aspartate receptor antagonist). Single- and paired-pulse transcranial magnetic stimulation (TMS) measures will be recorded for online LIFUS before and after drug intervention, and induction of offline LIFUS during placebo will be compared with its induction following the various drug interventions. Investigators predict that due to the differential effects of online and offline LIFUS on motor parameters, the mechanisms in which it alters the receptors and channels of interest will also be deferentially modulated.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Health Network, Toronto
• Treatments: Carbamazepine; Dextromethorphan; Lorazepam; Nimodipine

Criteria

Inclusion Criteria:

• Right-handed healthy subjects between the ages of 18-65 will be included for recruitment.

Exclusion Criteria:

• Diagnosed with any gait or postural disorders

• Major neurological disease or disorder

• Major musculoskeletal or nerve disorder, or disorder of hands, wrists and upper limbs

• History of stroke or seizure

• Diagnosed with dementia

• Diagnosed with myasthenia gravis or acute narrow angle glaucoma

• Has intracranial implant(s) or device(s)

• Has an implanted cardiac pacemaker or implantable cardioverter-defibrillator (ICD)

• Presence of metal implanted in body that is contraindicated in TMS

• Caffeine or chocolate consumption 1-2 hours before study sessions

• Consumption of grapefruit juice 24 hours before study sessions

• Alcohol consumption 24 hours before study sessions

• Pregnancy*

• Major depression/psychiatric disorder that in the opinion of the Investigator will affect patient's understanding of study procedures and willingness to abide by all procedures during the course of the study

• Regular usage of CNS active drugs or calcium channel blockers during or up to 2 weeks before participating in the study**

• Is on antipsychotics, marijuana, or other recreational drugs (including tobacco) that affect the nervous system

• Major cardiac, hematopoietic, liver, or kidney disease or infection

• Treated hypertension

• Hypersensitivity to benzodiazepines

• Hypersensitivity to calcium channel blockers

• Hypersensitivity to antitussives

• Hypersensitivity to anticonvulsants

• Regular usage of androgens, antibiotics, antifungals, antivirals, cardiovascular/gastrointenstinal drugs, muscle relaxants, and platelet aggregation inhibitors during or up to 2 weeks before participating in the study